Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis

Jerry A. Nick, Christopher D. Coldren, Mark W. Geraci, Katie R. Poch, Brian W. Fouty, James O'Brien, Michael Gruber, Simona Zarini, Robert C. Murphy, Katherine Kuhn, Don Richter, Kelly R. Kast, Edward Abraham

Research output: Contribution to journalArticle

201 Citations (Scopus)

Abstract

Recombinant human activated protein C (rhAPC) is a natural anticoagulant with potentially important anti-inflammatory properties. In humans with severe sepsis, rhAPC treatment reduces mortality, but mechanisms responsible have not been well characterized. Accumulation of activated neutrophils in the lungs and other organs during severe infection contributes to sepsis-induced organ dysfunction, including acute inflammatory lung injury. Because neutrophils express an APC receptor, we hypothesized that immunomodulatory effects of rhAPC occur, in part, via modulation of neutrophil responses. To examine this issue, we performed a double-blinded, placebo-controlled study of rhAPC in a human model of endotoxin-induced pulmonary inflammation. Administration of rhAPC significantly reduced leukocyte accumulation to the airspaces, independent of pulmonary cytokine or chemokine release. Neutrophils recovered from bronchoalveolar lavage fluid of volunteers receiving rhAPC demonstrated decreased chemotaxis ex vivo. Decreased neutrophil chemotaxis following exposure to rhAPC was confirmed in vitro. No differences were detected in gene expression, kinase activation, cytokine release, cell survival, or apoptosis of neutrophils recovered in the presence or absence of rhAPC. These studies demonstrate that rhAPC reduces both endotoxin-induced accumulation of leukocytes in the airspaces and neutrophil chemotaxis. These rhAPC-induced effects on neutrophil function may represent a mechanism by which rhAPC improves survival in patients with sepsis.

Original languageEnglish (US)
Pages (from-to)3878-3885
Number of pages8
JournalBlood
Volume104
Issue number13
DOIs
StatePublished - Dec 15 2004
Externally publishedYes

Fingerprint

Cell Migration Inhibition
Protein C
Endotoxins
Pneumonia
Neutrophils
Chemotaxis
Sepsis
Cytokines
Leukocytes
Lung
Chemokines
Acute Lung Injury
Gene expression
Anticoagulants
Bronchoalveolar Lavage Fluid
Anti-Inflammatory Agents
Phosphotransferases

ASJC Scopus subject areas

  • Hematology

Cite this

Nick, J. A., Coldren, C. D., Geraci, M. W., Poch, K. R., Fouty, B. W., O'Brien, J., ... Abraham, E. (2004). Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood, 104(13), 3878-3885. https://doi.org/10.1182/blood-2004-06-2140

Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. / Nick, Jerry A.; Coldren, Christopher D.; Geraci, Mark W.; Poch, Katie R.; Fouty, Brian W.; O'Brien, James; Gruber, Michael; Zarini, Simona; Murphy, Robert C.; Kuhn, Katherine; Richter, Don; Kast, Kelly R.; Abraham, Edward.

In: Blood, Vol. 104, No. 13, 15.12.2004, p. 3878-3885.

Research output: Contribution to journalArticle

Nick, JA, Coldren, CD, Geraci, MW, Poch, KR, Fouty, BW, O'Brien, J, Gruber, M, Zarini, S, Murphy, RC, Kuhn, K, Richter, D, Kast, KR & Abraham, E 2004, 'Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis', Blood, vol. 104, no. 13, pp. 3878-3885. https://doi.org/10.1182/blood-2004-06-2140
Nick, Jerry A. ; Coldren, Christopher D. ; Geraci, Mark W. ; Poch, Katie R. ; Fouty, Brian W. ; O'Brien, James ; Gruber, Michael ; Zarini, Simona ; Murphy, Robert C. ; Kuhn, Katherine ; Richter, Don ; Kast, Kelly R. ; Abraham, Edward. / Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. In: Blood. 2004 ; Vol. 104, No. 13. pp. 3878-3885.
@article{8ba50d40c2e5475599cb764f57456c0c,
title = "Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis",
abstract = "Recombinant human activated protein C (rhAPC) is a natural anticoagulant with potentially important anti-inflammatory properties. In humans with severe sepsis, rhAPC treatment reduces mortality, but mechanisms responsible have not been well characterized. Accumulation of activated neutrophils in the lungs and other organs during severe infection contributes to sepsis-induced organ dysfunction, including acute inflammatory lung injury. Because neutrophils express an APC receptor, we hypothesized that immunomodulatory effects of rhAPC occur, in part, via modulation of neutrophil responses. To examine this issue, we performed a double-blinded, placebo-controlled study of rhAPC in a human model of endotoxin-induced pulmonary inflammation. Administration of rhAPC significantly reduced leukocyte accumulation to the airspaces, independent of pulmonary cytokine or chemokine release. Neutrophils recovered from bronchoalveolar lavage fluid of volunteers receiving rhAPC demonstrated decreased chemotaxis ex vivo. Decreased neutrophil chemotaxis following exposure to rhAPC was confirmed in vitro. No differences were detected in gene expression, kinase activation, cytokine release, cell survival, or apoptosis of neutrophils recovered in the presence or absence of rhAPC. These studies demonstrate that rhAPC reduces both endotoxin-induced accumulation of leukocytes in the airspaces and neutrophil chemotaxis. These rhAPC-induced effects on neutrophil function may represent a mechanism by which rhAPC improves survival in patients with sepsis.",
author = "Nick, {Jerry A.} and Coldren, {Christopher D.} and Geraci, {Mark W.} and Poch, {Katie R.} and Fouty, {Brian W.} and James O'Brien and Michael Gruber and Simona Zarini and Murphy, {Robert C.} and Katherine Kuhn and Don Richter and Kast, {Kelly R.} and Edward Abraham",
year = "2004",
month = "12",
day = "15",
doi = "10.1182/blood-2004-06-2140",
language = "English (US)",
volume = "104",
pages = "3878--3885",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "13",

}

TY - JOUR

T1 - Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis

AU - Nick, Jerry A.

AU - Coldren, Christopher D.

AU - Geraci, Mark W.

AU - Poch, Katie R.

AU - Fouty, Brian W.

AU - O'Brien, James

AU - Gruber, Michael

AU - Zarini, Simona

AU - Murphy, Robert C.

AU - Kuhn, Katherine

AU - Richter, Don

AU - Kast, Kelly R.

AU - Abraham, Edward

PY - 2004/12/15

Y1 - 2004/12/15

N2 - Recombinant human activated protein C (rhAPC) is a natural anticoagulant with potentially important anti-inflammatory properties. In humans with severe sepsis, rhAPC treatment reduces mortality, but mechanisms responsible have not been well characterized. Accumulation of activated neutrophils in the lungs and other organs during severe infection contributes to sepsis-induced organ dysfunction, including acute inflammatory lung injury. Because neutrophils express an APC receptor, we hypothesized that immunomodulatory effects of rhAPC occur, in part, via modulation of neutrophil responses. To examine this issue, we performed a double-blinded, placebo-controlled study of rhAPC in a human model of endotoxin-induced pulmonary inflammation. Administration of rhAPC significantly reduced leukocyte accumulation to the airspaces, independent of pulmonary cytokine or chemokine release. Neutrophils recovered from bronchoalveolar lavage fluid of volunteers receiving rhAPC demonstrated decreased chemotaxis ex vivo. Decreased neutrophil chemotaxis following exposure to rhAPC was confirmed in vitro. No differences were detected in gene expression, kinase activation, cytokine release, cell survival, or apoptosis of neutrophils recovered in the presence or absence of rhAPC. These studies demonstrate that rhAPC reduces both endotoxin-induced accumulation of leukocytes in the airspaces and neutrophil chemotaxis. These rhAPC-induced effects on neutrophil function may represent a mechanism by which rhAPC improves survival in patients with sepsis.

AB - Recombinant human activated protein C (rhAPC) is a natural anticoagulant with potentially important anti-inflammatory properties. In humans with severe sepsis, rhAPC treatment reduces mortality, but mechanisms responsible have not been well characterized. Accumulation of activated neutrophils in the lungs and other organs during severe infection contributes to sepsis-induced organ dysfunction, including acute inflammatory lung injury. Because neutrophils express an APC receptor, we hypothesized that immunomodulatory effects of rhAPC occur, in part, via modulation of neutrophil responses. To examine this issue, we performed a double-blinded, placebo-controlled study of rhAPC in a human model of endotoxin-induced pulmonary inflammation. Administration of rhAPC significantly reduced leukocyte accumulation to the airspaces, independent of pulmonary cytokine or chemokine release. Neutrophils recovered from bronchoalveolar lavage fluid of volunteers receiving rhAPC demonstrated decreased chemotaxis ex vivo. Decreased neutrophil chemotaxis following exposure to rhAPC was confirmed in vitro. No differences were detected in gene expression, kinase activation, cytokine release, cell survival, or apoptosis of neutrophils recovered in the presence or absence of rhAPC. These studies demonstrate that rhAPC reduces both endotoxin-induced accumulation of leukocytes in the airspaces and neutrophil chemotaxis. These rhAPC-induced effects on neutrophil function may represent a mechanism by which rhAPC improves survival in patients with sepsis.

UR - http://www.scopus.com/inward/record.url?scp=10244229104&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10244229104&partnerID=8YFLogxK

U2 - 10.1182/blood-2004-06-2140

DO - 10.1182/blood-2004-06-2140

M3 - Article

VL - 104

SP - 3878

EP - 3885

JO - Blood

JF - Blood

SN - 0006-4971

IS - 13

ER -